REC-2282 not checked
Recursion Pharmaceuticals Inc. · AR-42 · OSU-HDAC42
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive REC-2282 3 times per week orally for 3 weeks followed by 1 week off for a 4-week cycle.”In the company’s words, NCT05130866 on ClinicalTrials.gov
- Tested for
- Neurofibromatosis Type 2
- Main trialPhase 2/3
- “This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in participants with progressive NF2 mutated meningiomas.”In the company’s words, NCT05130866 on ClinicalTrials.gov
- Other names
- AR-42 · OSU-HDAC42 · NSC-D736012
Other drugs for Neurofibromatosis Type 2
- TrineuminPRG Science & Technology Co., Ltd. · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Terminated | 18 Aug 2025 | Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026